Supplementary Appendix Appendix 1. Scoping Review for the Related Literature
Important note: Given that the available literature quantifying malaria care quality from previous studies was limited and not comparable across the different settings, we only used this scoping review to inform the related literature in the study. The literature found from this scoping review were not in any form used to estimate or to quantify malaria care quality in the study countries. The study used the Malaria Indicators Survey data, which provide patient-level information on febrile children under five.
A scoping review to examine previous studies pertaining to quality of malaria care among children under five in low-and middle-income countries (LMICs) was carried out from October 1 to 15, 2018. We searched PubMed using predefined search terms in regards to quality of malaria care (appendix). Only English, peer-reviewed journal articles published in the last five years were included. Using Covidence, a second reviewer blinded to the primary reviewer's decisions checked the article selection and data extraction. A third reviewer resolved any conflicts in the review decisions. We found that while an extensive array of evidence about access to malaria care insecticide-treated bed nets, diagnostics, and treatments, as well as quality of malaria diagnostic tests and drugs are available, we know much less about the quality of malaria care provision and how quality of malaria care compares across LMICs.
In view of the broad scope of this inquiry, we followed published guidance on scoping reviews. This involved use of a broad search strategy to identify relevant studies; selection of studies according to inclusion and exclusion criteria; charting the data; collating, summarizing, and reporting the results; and placing particular emphasis on consultations with relevant experts. We searched PubMed using predefined search terms related to quality of malaria care. Only English, peer-reviewed journal articles published in the last five years were included, therefore letters, editorials, conference proceedings, and grey literature, such as reports from government agencies, were excluded in the study. Abstracts and titles of articles are reviewed first in regards to our inclusion and exclusion criteria. Then, full-text articles were reviewed. Using Covidence, a second reviewer blinded to the primary reviewer's decisions checked the article selection and data extraction. Differences of opinion were discussed, and a third reviewer resolved any conflicts. 6. Does it focus on quality of malaria care service delivery (in terms of case finding, diagnosis, and treatment? 7. Does it focus on quality of the malaria diagnostic tools (e.g. mRDTs, microscopy) or drugs (artemisinin, etc)? If yes, please exclude these articles.
Pre-defined
Other areas for exclusion:
1. The paper is focusing on quality assessment of pharmaceutical products, surgical interventions, diagnostic tools or vaccines for roll-out 2. The paper is a viewpoint, protocol for a study, call for papers, editorials, opinion paper, correspondence, letter, or news article.
3. The paper focuses on prospective studies, proposals, simulations, or mathematical modeling of potential effects of a program/intervention 7. The paper focuses on improvements on information technology infrastructure (e.g. communications systems, databases, or surveillance systems) 8. The paper focuses on specialized areas: military or troops, conflict-affected states, including focusing on refugees or for humanitarian contexts 8. The paper focuses on determinants of health outcomes (e.g. quality of life) without assessment of any existing programs implemented to improve quality of health care services; thus, focuses on quality of life instead of quality of care 9. The paper focuses on developing approaches or solutions for considerations in the future' 10. The paper focuses on traveler's malaria or on pregnant women to protect their unborn from malaria 11. The paper focuses on modeling possible malaria scenarios 12. The paper focuses on costing of malaria treatment options or other interventions. 
Full Text Studies Included

Appendix 2. Country context gathered from malaria reports
Country context. There were 114 million children under-five living in the 25 study countries, of which 215 per 1000 population were at risk of malaria resulting to a mean of 8.3% (n=288,400) malaria deaths ( Table 1 ). The highest percentage of malaria deaths among children under-five were in Burkina Faso (24.6%, n=15,556) in 2014 followed by Mali (24.4%, n=20,251) in 2015. The lowest recorded malaria deaths among children under-five were in Cambodia (0.3%, n=145) in 2005 and Ethiopia (0.8%, n=1,550) in 2016. Across all study countries, the average P. Falciparum endemicity is 86%. The highest recorded was in Swaziland at 99%, followed by Malawi and Mozambique both at 90%. The lowest recorded was in Ethiopia at 65%, followed by Burkina Faso (80%) and Nigeria (85%). WHO recommends prompt malaria diagnosis either by microscopy or mRDTs in all patients with suspected malaria before treatment is administered. [14] In all countries but Cambodia, Plasmodium Falciparum is the usual causative agent of malaria as it is highly endemic in these countries. WHO recommends artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated malaria caused by P. Falciparum parasite. ACTs combine two active ingredients with different mechanisms of action and are the most effective antimalarial medicines available today. As such, monotherapies or use of only one drug were not recommended since use of single drugs may promote the development of artemisinin resistance. [14] Following these guidelines, we then selected relevant testing and treatment variables available in the MIS. Thus, we defined poor malaria care quality as those instances wherein a patient encountered the following during each treatment cascade:
Country Year
1. Malaria testing -a febrile patient was not blood tested, 2. Malaria treatment provision -a febrile patient was treated with one antimalarial drug or three or more antimalarial drugs. Given that not all countries provide an account of the antimalarial drugs given to the patient and since the data on antimalarial drugs were based on the women's recall of drugs given to their child under-five, we presupposed that reporting provision of two antimalarial drugs suggest artemisinin-based combination therapies (ACTs) provision; thus, may have been appropriate care. Otherwise, if a patient was provided none, one, or three or more antimalarial drugs, the treatment was considered inappropriate and were counted towards poor quality of care. The WHO recommended care for treating uncomplicated P. Falciparum malaria cases with one of the following ACTs: artemether + lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, dihydroartemisinin + piperaquine, or artesunate + sulfadoxine-pyrimethamine. [14] 3. Malaria treatment timeliness -a febrile patient receiving malaria care only after twentyfour hours from the onset of fever. It would have been ideal to determine timely care by examining whether or not they received malaria care within twenty-four hours from the time they sought care or when they first saw a healthcare provider. Unfortunately, existing data only provide time from the onset of fever.
We limited our analysis among febrile children who sought medical care. We then calculated the number of times the patient had inappropriate care out of the total number of possible treatment encounters per patient. See flow diagram in the next page for the number of eligible for each treatment cascade. We are able to estimate this patient-level outcome for the four study countries with actual malaria laboratory test results, which allow us to determine which patients had malaria. Our outcome of interest was the proportion of cases that were incorrectly managed, either due to undertreatment or overtreatment. We define undertreatment as any instance when a febrile child under-five had positive malaria test results, but did not receive any antimalarial drug (not treated), or received only one antimalarial drug instead of the WHO recommended combination drugs (treated with one drug). [14] In contrast, we define overtreatment as any instance when a febrile child under-five had positive malaria test results, but was treated with three or more antimalarial drugs, or had negative malaria test results, but was treated with any number of antimalarial drugs.
Of the four countries that had additional data on malaria laboratory test results (Angola, Ghana, Nigeria, and Senegal), a mean of 35% of cases were incorrectly managed (Table 4) . Undertreatment was noted in 26% (n=1,992) of cases, while overtreatment occurred at 9% (n=952). Among those who were undertreated, 81% of cases with positive malaria test results were not treated with any antimalarial drug and 13% were treated with one antimalarial drug. Among those who were overtreated, 0.41% of cases with positive malaria test results were treated with three or more antimalarial drugs, while for cases with negative malaria test results, about 13% were treated with antimalarial drugs (10% with one antimalarial drug, 2% with ACT, and 0.18% with three or more drugs). Underand overtreatment calculations were not weighted to get the true proportions of care for each treatment cascade described above. 
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